San Diego, California: ? Biocept, Inc., a privately?held CLIA?certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in blood samples from cancer patients, announced today that the US Patent and Trademark Office has allowed its patent application covering its microchannel capture device deve...

San Diego, California: – Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced today the publication of a paper describing an analysis of CTC capture using its proprietary Cell Enrichment and Extraction (CEETM) platfor...

San Diego, California: ? Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, and Clarient, Inc. (a GE Healthcare Company) today announced a collaboration on the commercialization of a proprietary blood test for CTCs in breast cancer...

Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer. As CFO, Mr. Kachioff will be responsible for management of the company’s accounting, finance, treasury, investor relations, risk management and information systems functions. Kachioff has more than 20 years...

Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3?7. The poster presentation is based on studies performed utilizing Biocept’s proprietary OncoCEE™ (Oncology Cell Enri...

San Diego, California: ? Biocept, Inc., a privately?held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction (CEE...

SAN DIEGO / — Biocept, Inc. announced today that Lyle Arnold, PhD and Michael Dunn, MBA have joined Biocept’s Management Team. Dr. Arnold will serve as Senior Vice President and Chief Scientific Officer (CSO) and Mr. Dunn will act as the Senior Vice President, Corporate Development.
“I am very excited about the addition...

The Board of Biocept, Inc. announced today that David F. Hale has joined the Board as Executive Chairman and Ivor Royston, M.D. as a Director. Mr. Hale and Dr. Royston first worked together at Hybritech, San Diego’s first biotech company, of which Dr. Royston was a co?founder and director, and Mr. Hale served as President and COO and as CE...